Adcendo raises $135m as ADC funding frenzy continues

Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and...

The first-in-class FGFR3 ADC of Qide Pharma commences clinical trials

Blenrep + BorDex combination accepted for review by US FDA

Sacituzumab Tirumotecan Earns Approval in China for Pretreated Advanced TNBC

AstraZeneca’s Enhertu drug added to China’s state insurance list